Benjamin Ehst
Dermatology · Portland, ORNPI 1740320068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,071,769 of the $1,517,007 with a category attached, or 70.7%. 23 manufacturers reported payments, led by Lilly USA, LLC at 27.9% of the total. Among dermatology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,781 payments — averaging $851.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$423K
- Sanofi$213K
- Novartis$193K
- Regeneron Healthcare Solutions, Inc.$135K
- LEO Pharma Inc.$122K
- AbbVie$113K
- plus $317K from 17 others
Across 2,559 payments — averaging $2590.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.6M
- AbbVie$1M
- Janssen Research & Development, LLC$696K
- Sanofi US Services Inc.$662K
- Amgen$557K
- Takeda Pharmaceuticals U.S.A., Inc.$500K
- plus $1.5M from 8 others
What the payments were for
- Consulting fees$310,85220%
- Speaking & faculty fees$1,071,76971%
- Travel & lodging$98,3546%
- Food & beverage$26,7402%
- Education$9,2931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 496 | $422,807 |
| Sanofi | 153 | $213,461 |
| Novartis | 218 | $192,896 |
| Regeneron Healthcare Solutions, Inc. | 151 | $135,465 |
| LEO Pharma Inc. | 121 | $121,916 |
| AbbVie | 141 | $113,450 |
| UCB, Inc. | 97 | $87,964 |
| Incyte Corporation | 50 | $44,793 |
| Johnson & Johnson(2 entities) | 142 | $37,377 |
| LEO Pharma AS | 11 | $36,673 |
| Dermavant Sciences, Inc. | 27 | $34,173 |
| Organon | 25 | $26,695 |
| E.r. Squibb & Sons, L.L.C. | 43 | $21,779 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 32 | $16,342 |
| Sun Pharmaceutical Industries Inc. | 7 | $8,263 |
| Eli Lilly | 1 | $863 |
| Pfizer | 36 | $582 |
| Arcutis Biotherapeutics, Inc. | 11 | $545 |
| Amgen | 6 | $472 |
| Galderma Laboratories, L.p. | 9 | $228 |
| Boehringer Ingelheim | 1 | $142 |
| Sanofi-aventis U.S. LLC | 2 | $69 |
| Janssen Research & Development, LLC | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,517,007 in reported general payments places this provider in the 95th percentile of 175 dermatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 17 | $355,865 |
| BimzelxBimekizumab-Bkzx | 13 | $189,061 |
| Acitretin | 11 | $5,788 |
| Clobetasol Propionate | 27 | $2,674 |
| MethotrexateMethotrexate Sodium | 15 | $239 |
| Triamcinolone Acetonide | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Bimzelx | $87,964 | $189,06113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 dermatology providers in Oregon.
Other dermatology in Portland
- Andrew BlauveltPortland$1.8M
- Jason HawkesPortland$1.5M
- Eric SimpsonPortland$1.4M
- Alex Ortega LoayzaPortland$122K
- Omar QutubPortland$107K
- Paul HaunPortland$85K
- Kathryn SchwarzenbergerPortland$34K
- Jon HanifinPortland$25K
- Phoebe RichPortland$17K
- Tracy FunkPortland$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.